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ABSTRACT 
Objectives: Carvedilol (CVD) is a nonselective β-adrenergic blocker that suffers from low absolute bioavailability (25-35%) due to first-pass 
metabolism. CVD-loaded buccal tablets were developed as a promising approach to overcome this limitation. 
Methods: The bilayers tablets were prepared by the direct compression technique. CVD-containing layer was based on one of four high molecular 
weight polymers; hydroxy propyl methylcellulose K15M (HPMC), Polyethylene oxide WSR N-750 (PEO), chitosan (CH) and Eudragit® RS-100 (EUD). 
An occlusive backing of ethylcellulose 20 (Ethocel®) was adopted as a second layer. The tablets were characterized for weight variation, thickness, 
friability % and drug content. Further studies were conducted to evaluate their swelling indices, surface pH, in vitro adhesion retention periods and 
in vitro drug release profiles. 
Results: The prepared tablets followed the compendial requirements for thickness, friability %, drug content and weight variation. The surface pH 
of all tablets ranged from 6.43 to 7.44 while their adhesion retention periods varied from 3.12 to 4.24 h. The best achieved system (PEO-based 
matrix; F4) displayed a reasonable adhesion retention period and a promising sustained drug release profile, over at least 8 hours, following non-
fickian diffusion kinetics. This could indicate the contribution of swelling and erosion mechanisms for drug release. 
Conclusions: The current work succeeded in developing and evaluation of promising mucoadhesive CVD matrices suitable for buccal 
administration. Further pharmacokinetic and clinical studies are suggested to confirm the ability of the best achieved system to avoid the first pass 
metabolism of CVD and improve patient compliance. 
Keywords: Carvedilol, Buccal, Bilayer tablets, Polymers. 
 
INTRODUCTION 
Most of clinicians and patients prefer the oral route for 
administration of drugs. In fact, many drugs cannot be delivered 
effectively through this route as they may be subjected to 
extensive first pass metabolism in liver which decrease its oral 
bioavailability [1]. 
Buccal drug delivery systems have superior advantages over the 
traditional oral route of administration such as avoiding the first 
pass hepatic metabolism, ease of administration especially for 
persons which cannot be dosed orally. Moreover, it can be easily 
removed from the buccal cavity in case of toxicity [2-3]. 
The oral cavity is considered as a very unique and preferable site of 
trans mucosal drug delivery to achieve a systemic effect which enables 
the drug to enter directly to the general circulation and thereby bypass 
the hepatic first pass metabolism, gastrointestinal tract problems and 
many problems of the conventional oral route [4]. 
Carvedilol (CVD) is a non-selective β-adrenergic blocker which has 
been widely used in the treatment of hypertension and heart failure. 
CVD is well absorbed from the gastrointestinal tract but its 
bioavailability is low (25-35%) due to extensive first pass 
metabolism [5, 6]. 
Most of the studies dealing with CVD buccal tablets, films or 
patches focused on the use of low viscosity grades of polymers. 
Outside this conceptual framework, the current study explored 
the potential of high molecular weight polymers on the 
physicochemical properties of the developed CVD bilayers buccal 
tablets. This work aimed to develop matrices showing more 
promising adhesion retention periods to allow more sustained 
drug release profiles. In fact, the avoidance of the first pass 
metabolism, the reduction of the dosing frequency as well as the 
improvement in patient compliance are extra targets to be 
validated in the upcoming work. 
MATERIALS AND METHODS 
Materials 
Carvedilol was kindly provided by GNP (6th of October City, Egypt). 
Eudragit® RS-100 (EUD) was gifted by Evonic Röhm GmbH, 
(Darmstadt, Germany). Polyethylene oxide WSR N-750 (PEO)[MW 
300 kDa], Ethylcellulose 20 (Ethocel®) and Hydroxypropyl 
methylcellulose K15M (HPMC) were donated by Dow Chemical 
Company(Midland, US). High molecular weight chitosan (CH) [190-
375kDa, degree of deacetylation>75%, viscosity 800-2000 cps were 
purchased from Sigma-Aldrich Chemical Co. (St. Louis, US). Mannitol 
was acquired from Blackburn Distributions LTD (Lancashire, 
England). Magnesium stearate was derived from CG Chemikalien 
(Laatzen, Germany). Talc was purchased from El-Nasr 
Pharmaceutical Chemicals Co. (Abu Zaabal, Egypt). Other chemicals 
(analytical grade) were used as received. 
Methods 
Preparation of CVD bilayer buccal tablets 
In an attempt to achieve uni-directional drug release towards the 
buccal mucosa, bilayer buccal tablets were prepared in which the 
Ethocel® outer layer served as an occlusive backing layer while CVD 
was loaded in the primary polymer layer. 
Twelve primary layers, each containing 6.25 mg carvedilol, were 
prepared by direct compression using a single punch tablet press 
machine (Royal artist, Bombay, India) equipped with flat punches (7 
mm). The respective powders, shown in table (1), including CVD, a 
polymer (HPMC K15M, CH, PEO, Eud), and a filler (mannitol) were 
separately passed through sieve no. 20. The investigated drug: 
polymer ratios were 1: 1, 1: 5 and 1: 10. The sieved powders were 
mixed for 10 min using a pestle and mortar. Finally, the lubricants 
(magnesium stearate and talc) were added and gently mixed for 
another 3 min with the previously blended powders. Accurate 
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weights of each mixture (100 mg) were pressed in the tablet press 
machine to produce the desired primary layers. Accurate weights of 
Ethocel® (50 mg) were pressed in the tablet machine over the 
primary layers to produce the desired bilayer buccal tablets (F1–
F12). The tablet hardness was kept constant in all batches at 5–5.5 
kg/cm2 using a Monsanto hardness tester (St. Louis, MO). 
Physicochemical characterization of the tablets 
Random tablets were selected from each batch (representing each 
formula) and were accurately weighed. The individual weights of 20 
tablets were compared to their average weight. The thickness of the 
tablets was determined using a vernier caliper (For-bro Engineers, 
Mumbai, India). The results are expressed as mean values (±SD) of 
10 tablets. 
According to USP specifications [8], 20 tablets were dedusted and 
placed in the drum of a tabletfriabilator (FAB-2, Logan Instruments 
Corp., NJ, USA)adjusted to rotate at a speed of 25 rpm. After 4 min, 
the tablets were removed, de dusted, and accurately weighed. The 
percent weight loss was determined relative to their original weight. 
The drug content uniformity within tablets was determined 
spectrophotometrically (1601-PC Double beam spectrometer, 
Shimadzu, Kyoto, Japan) at a wavelength of 287 nm. Briefly, ten 
tablets were randomly selected.  
Each tablet was crushed using a pestle and mortar. Subsequently, 
each powdered tablet was extracted in 100 ml of Sorensen’s 
phosphate buffer pH 6.8 containing Tween 80 (0.5%, v/v). The 
solution was filtered, and the drug content was determined after 
dilution with the same buffer. The results are expressed as mean 
values (±SD) of ten samples [9]. 
Surface pH study 
The tablet was allowed to swell by keeping it in contact with 2 ml of 
phosphate buffer (pH 6.8) for 2 h at room temperature. The pH was 
measured by bringing the electrode of the pH meter in contact with 
the surface of the tablet and allowing it to equilibrate for 1 min. The 
surface pH for each tablet was determined in triplicate and the 
mean±SD was calculated [10]. 
Swelling study 
The swelling index (SI) for each tablet was determined in triplicate, 
and the mean (±S. D.) was calculated. The original weights of CVD 
tablets were determined (W1). The tablets were placed on separate 
agar plates (1%, w/w) and then incubated with Sorensen’s 
phosphate buffer (5 ml, pH 6.8) at 37±0.5 °C. At regular time 
intervals (2 h) until 8 h, the tablets were removed from the plates 
and the excess surface water was removed carefully with filter 
paper. The swollen tablet was then reweighed (W2) and the swelling 
index was calculated using equation (1) [11]: 
Swelling Index = (W2–W1)
W1
(1) 
Estimation of the adhesion retention period 
The adhesion retention period of the tablets was estimated, in 
triplicate, in a USP Dissolution Tester (type II) (VK 7000 Dissolution 
Testing Station, Vankel Industries, Inc., NJ, USA).  
Briefly, the primary layer of the tablet was wetted with phosphate 
buffer (pH 6.8), attached to the center of an agar plate (1%, w/w) by 
applying light force with a fingertip for 20 s and finally left for 5 min 
for equilibration. 
The tablet-fixed agar plates were immersed into the dissolution 
medium (Sorensen’s phosphate buffer (pH 6.8) containing Tween 80 
(0.5% v/v), 500 ml) at the lowest point of the dissolution flask. The 
paddles rotated at a speed of 50 rpm. The time elapsed till the 
detachment of the tablets, at 37±0.5 °C, was visually recorded as the 
adhesion retention period [12]. 
 





















F1 6.25 6.25 - - - 85.5 1 1 50 
F2 6.25 31.25 - - - 60.5 1 1 50 
F3 6.25 62.5 - - - 29.25 1 1 50 
F4 6.25 - 6.25 - - 85.5 1 1 50 
F5 6.25 - 31.25 - - 60.5 1 1 50 
F6 6.25 - 62.5 - - 29.25 1 1 50 
F7 6.25 - - 6.25 - 85.5 1 1 50 
F8 6.25 - - 31.25 - 60.5 1 1 50 
F9 6.25 - - 62.5 - 29.25 1 1 50 
F10 6.25 - - - 6.25 85.5 1 1 50 
F11 6.25 - - - 31.25 60.5 1 1 50 
F12 6.25 - - - 62.5 29.25 1 1 50 
 
In vitro drug release studies 
The drug release studies were performed in a USP Dissolution 
Tester Apparatus, type-II at 37±0.5 °C. The dissolution medium (500 
ml) was Sorensen’s phosphate buffer (pH 6.8) containing Tween 80 
(0.5% v/v). The paddles rotated at a speed of 50 rpm. The tablet was 
supposed to release the drug from the primary layer only hence the 
backing side of tablet was fixed to a glass slide with cyanoacrylate 
adhesive. The loaded-glass slide was placed at the bottom of the 
dissolution vessel. At definite time intervals, aliquot samples (5 ml) 
from the dissolution medium were withdrawn and filtered through a 
cellulose acetate membrane (0.45 μm) [13]. Replacement with an 
equal volume of fresh medium was done at each time of withdrawal. 
The drug content of each sample was determined as previously 
described. The drug released percentages after 1 h (P1h) and 8 h 
(P8h) were calculated. The results are expressed as mean values (±S. 
D.) of three determinations. The data were statistically analyzed 
(SPSS 14.0, Chicago, USA) applying one-way ANOVA at P value<0.05. 
Post hoc multiple comparisons between formulae were performed 
using the least square difference test. 
Kinetic modeling of dissolution profiles 
The drug release profiles were fitted to zero-order, first-order, 
Higuchi diffusion model and Korsmeyer–Peppas model (equation 2) 




� = ktn(2) 
Where, �Mt
M∞
�is an estimate of the drug dissolvedfraction at time t, k is 
a constant related to the geometric and structural characteristics of 
matrix, and n is the drug release exponent. The log value of the drug 
dissolved fraction was plotted against log time in equation (3) to 
determine the drug release exponent (n). 
log �Mt
M∞
� = log k+n log t(3) 
The n has the limiting value of 0.45 for diffusion (Fickian) controlled 
release, n values falling between 0.45 and 0.89 are correlated to 
anomalous (non-Fickian) controlled release. Thenon-Fickian 
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kinetics corresponds to coupled polymer diffusion/relaxation 
[15,16] Values greater than 0.89 correspond to relaxation (Case II 
transport) controlled release. 
RESULTS AND DISCUSSION 
Altering the polymer combinations did not affect the 
physicochemical properties of the investigated CVD buccal tablets; 
as shown in table (2). The thickness of all tablet batches was 
relatively small ranging from 2.90to 3.1 mm. An average thickness of 
3 mm would reduce the foreign body sensation and consequently 
improve patient compliance. All the tablets complied with the 
pharma copoeial specificationsfor weight variation, friability and 
drug content uniformity. The average weight of the tablets was in 
close approximation to the theoretical weight viz. 150 mg. Statistical 
analysis of data revealed a non-significant difference (P<0.05). A 
coefficientof variation of less than 3% could indicate compliance 
withthe USP Pharmacopeial requirements for weight [17]. 
A good mechanical resistance would be expected for all formulae as 
a result of their low friability (<1%). This could be expected to 
minimize the hazards of matrix erosion during shipping and 
transportation. The drug content of the individual units ranged from 
97.42%to 103.12%. These values were much lower than those 
permitted by USP (90–110%) for drug content. This could be an 
indication to the suitability of the employedpowder mixing 
technique to prepare CVD tablets. 
The surface pH of all the tablets ranged from 6.43 to 7.44, which was 
close to the pH of saliva (5.5–7). Hence, it could be assumed that the 
developed formulations might cause no irritation in the oral cavity 
upon clinic application. 
The swelling profiles of CVD tablets are shown in fig. (1). It is clear 
that the swelling indices of all CVD tablets increased with time 
where the investigated hydrophilic polymers (CH, HPMC, EUD, PEO) 
are expected to gradually absorb water. Maximum swelling was 
achieved after 4 hours; after which the matrices showed varied 
degrees of erosion in the medium. These findings were in line with 
those reported by Chaudhari and Harsulkar [18] who found that 
maximum swelling of carbopol-chitosan based matrices containing 
CVD was attained in 5 hrs. They observed that the polymers started 
eroding slowly in the swelling medium after this period. In fact, the 
swelling of polymers is the corner stone in its bioadhesive behavior 
which plays a very important role in maintaining the dosage form in 
its proper place in buccal cavity for uniform and prolonged drug 
action. The more the degree of polymer hydration the more the bio 
adhesion is, till it reaches a point where over hydration leads to a 
sudden drop in adhesion force due to disentanglement at the polymer 
tissue surface [19]. It was revealed that PEO-based matrices showed 
high swelling indices. The erosion of the matrices after 4 hours could 
be related to the water soluble nature of this polymer. In contrast, the 
swelling indices of CH-and HPMC-based matrices were much lower 
and showed gradual erosion.  
All systems showed promising adhesion retention periods varying 
from 3.12 to 4.24 h; suggesting good adhesion to the buccal surfaces 
upon clinic application.  
The mechanism of the interaction of the hydrated tablets with the 
agar tablets was explained by Tadros and Fahmy [12] who 
developed the adopted procedure. They showed that upon contact 
with agar plates in the dissolution medium, the hydrated tablets 
produce gelling networks able to interact with agar as a result of the 
physical entanglement and secondary bonding like H-bonding and 
Van der Waals attractions. 
 
 
Fig. 1: Swelling indices of CVD buccal tablets versus time 
(mean±SD, n=3) 
 
The higher medium uptake ability of the developed matrices, as 
proved in the swellingstudies, would increase the mobility of 
molecules and consequently facilitates the interaction and 
interpenetration with agar. It should be noted that very strong bio 
adhesion is not targeted since this could damage the epithelial lining 
of the buccal mucosa. 
The in vitro drug release profiles revealed that the release of 
carvedilol from different formulations varies with the type and ratio 
of mucoadhesive polymer used in its formation as shown in fig. (2-
5). The aim of the current work was to develop promising sustained 
release matrices capable of controlling the release of CVD over 8 
hours, at least. To achieve this goal lower P1h and higher 
P8hpercentages are required. Inverse correlations were observed 
between the polymer ratio and P8h. In other words, the higher the 
polymer ratio in the developed matrix, the lower the P8h percentage. 
CH-based matrices showed significantly (P<0.05) higher P1h 
percentage. On the other hand, EUD-based matrices showed 
significantly (P<0.05) lower P8h percentage. More promising results 
were achieved with HPMC-and PEO-based matrices who achieved 
good compromise between P1h and P8h percentages. F4 would be 
suggested to be the best achieved matrix where the P1h. and P8h were 
15.66 and 85.89%, respectively. 
All systems fitted to Korsmeyer-Peppas model. HPMC-based 
matrices were best fitted to Non-Fickian kinetics, indicating the 
positive impact of the diffusion and matrix erosion mechanisms in 
the drug release kinetics [15]. CH-based matrices were best fitted to 
Higuchi model while case II kinetic modeling was predominant in 
EUD-and PEO-based ones, indicating the limited influence and the 
pronounced contribution of the matrix erosion in drug release 
kinetics of the former and the latter matrices, respectively. 
 
Table 2: Characterization of CVD buccal tablets (mean±SD) 



















F1 150.32±0.51 2.9±0.1 101.92±1.13 0.25 6.92±0.28 3.72±0.16 28.96±0.27 86.83±1.64 
F2 152.42±0.32 2.9±0.1 99.27±1.33 0.34 7.12±0.17 3.81±0.24 13.66±1.6 57.56±1.53 
F3 148.63±0.25 3.1±0.1 102.92±1.16 0.21 6.72±0.19 4.22±0.15 10.67±1.49 33.49±1.43 
F4 149.22±0.26 2.9±0.2 97.42±0.33 0.29 6.43±0.29 3.95±0.04 15.66±1.51 85.89±2.54 
F5 154.74±0.27 2.9±0.1 101.52±1.23 0.32 7.44±0.18 4.10±0.17 8.53±1.81 76.42±2.68 
F6 150.72±0.33 3.1±0.1 102.31±1.24 0.37 6.71±0.15 4.24±0.11 4.83±1.39 72.19±1.12 
F7 147.34±0.32 2.9±0.2 98.55±1.11 0.34 6.62±0.11 3.24±0.09 50.66±1.83 94.63±1.24 
F8 148.61±0.32 3.1±0.1 103.12±0.96 0.49 7.22±0.06 3.24±0.14 36.75±1.59 77.39±1.63 
F9 149.41±0.28 3.1±0.1 97.62±1.98 0.27 6.52±0.09 3.92±0.08 35.77±2.51 69.92±1.55 
F10 150.93±0.49 3.1±0.1 99.34±1.35 0.29 7.12±0.15 3.12±0.26 13.28±1.24 71.79±2.68 
F11 150.12±0.30 2.9±0.1 100.91±1.34 0.31 6.82±0.11 3.25±0.09 8.49±1.12 49.53±1.55 
F12 151.72±0.32 2.9±0.2 99.27±0.31 0.36 6.91±0.12 3.85±0.14 4.39±2.22 40.62±1.24 
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Fig. 2: In vitro release profiles of HPMC-based CVD bilayer buccal tablets (F1-F3) in Sorensen’s phosphate buffer (pH 6.8) containing 
Tween 80 (0.5% v/v) at 37±0.5 °C (mean±SD, n = 3) 
 
 
Fig. 3: In vitro release profiles of PEO-based CVD bilayer buccal tablets (F4-F6) in Sorensen’s phosphate buffer (pH 6.8) containing Tween 
80 (0.5% v/v) at 37±0.5 °C (mean±SD, n = 3) 
 
 
Fig. 4: In vitro release profiles of CH-based CVD bilayer buccal tablets (F7-F9) in Sorensen’s phosphate buffer (pH 6.8) containing Tween 
80 (0.5% v/v) at 37±0.5 °C (mean±SD, n = 3) 
 
 
Fig. 5: In vitro release profiles of EUD-based CVD bilayer buccal tablets (F10-F12) in Sorensen’s phosphate buffer (pH 6.8) containing 
Tween 80 (0.5% v/v) at 37±0.5 °C (mean±SD, n = 3) 
Ahmed et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 9, 172-176 
176 
Table 3: Mathematical modeling and release kinetics of CVD buccal tablets 
 Zero-order plots First-order plots Higuchi Korsmeyer-Peppas plots  
Form. code Corr. coeff. (R2) Corr. coeff. (R2) Corr. coeff. (R2) Corr. coeff.  
(R2) 
Release exponent (n) The best  
fitting model 
F1 0.966 0.988 0.995 0.999 0.582 Non-Fickian 
F2 0.993 0.996 0.992 0.999 0.661 Non-Fickian 
F3 0.966 0.980 0.997 0.998 0.597 Non-Fickian 
F4 0.969 0.984 0.989 0.996 0.865 Non-Fickian 
F5 0.974 0.982 0.978 0.997 1.278 Case II transport 
F6 0.982 0.983 0.974 0.994 1.577 Case II transport 
F7 0.965 0.965 0.997 0.998 0.275 Diffusion 
F8 0.987 0.962 0.973 0.989 0.258 Diffusion 
F9 0.978 0.977 0.983 0.998 0.269 Diffusion 
F10 0.950 0.954 0.976 0.982 0.983 Case II transport 
F11 0.983 0.990 0.986 0.991 1.053 Case II transport 
F12 0.987 0.987 0.972 0.992 1.059 Case II transport 
 
CONCLUSION 
The current work succeeded in developing promising mucoadhesive 
CVD matrices suitable for buccal administration. The best achieved 
system (F4) displayed a high swelling index, reasonable adhesion 
retention period and a suitable sustained drug release profile. 
Further studies should be conducted in healthy volunteers to 
confirm these results and estimate the drug pharmacokinetics 
following buccal administration. 
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